Invus adds $150M to Lexicon investment

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) raised $150 million from an affiliate of Invus by selling shares in a private placement

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE